Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Reyes Jiménez-Bárcenas"'
Autor:
Tomás José González-López, Abelardo Bárez, Ángel Bernardo-Gutiérrez, Silvia Bernat, Fernando Fernández-Fuertes, José María Guinea de Castro, Reyes Jiménez-Bárcenas, Isidro Jarque
Publikováno v:
Platelets, Vol 35, Iss 1 (2024)
AbstractImmune thrombocytopenia (ITP) is a common autoimmune hematological disorder. Despite this, diagnosis is still challenging due to clinical heterogeneity and the lack of a specific diagnostic test. New findings in the pathology and the availabi
Externí odkaz:
https://doaj.org/article/2038cada39704be3a53bc1866881af5e
Autor:
Tomás José González-López, Abelardo Bárez, Angel Bernardo-Gutiérrez, Silvia Bernat, Mariana Canaro-Hirnyk, Laura Entrena-Ureña, Fernando Fernández-Fuertes, José María Guinea de Castro, Reyes Jiménez-Bárcenas, Cristina Pascual-Izquierdo, Blanca Sánchez-González, Isidro Jarque
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 2, Pp 303-315 (2022)
Abstract Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease with highly variable presentation, characteristics, and clinical course. Thrombocytopenia is a common complication of many viral infections, including SARS-CoV-2. In add
Externí odkaz:
https://doaj.org/article/9d60d1cdd8804819acff85433f980a34
Autor:
María Eva Mingot-Castellano, José María Bastida, Gonzalo Caballero-Navarro, Laura Entrena Ureña, Tomás José González-López, José Ramón González-Porras, Nora Butta, Mariana Canaro, Reyes Jiménez-Bárcenas, María del Carmen Gómez del Castillo Solano, Blanca Sánchez-González, Cristina Pascual-Izquierdo, on behalf of the GEPTI
Publikováno v:
Pharmaceuticals, Vol 15, Iss 7, p 779 (2022)
Primary immune thrombocytopenia (ITP) is an autoimmune disorder that causes low platelet counts and subsequent bleeding risk. Although current corticosteroid-based ITP therapies are able to improve platelet counts, up to 70% of subjects with an ITP d
Externí odkaz:
https://doaj.org/article/8391b7c27bbe4a9cbc81a84cc39a076f
Autor:
María Eva Mingot-Castellano, Nora Butta, Mariana Canaro, María del Carmen Gómez del Castillo Solano, Blanca Sánchez-González, Reyes Jiménez-Bárcenas, Cristina Pascual-Izquierdo, Gonzalo Caballero-Navarro, Laura Entrena Ureña, Tomás José González-López, on behalf of the GEPTI
Publikováno v:
Vaccines, Vol 10, Iss 6, p 961 (2022)
Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally
Externí odkaz:
https://doaj.org/article/9a6016f6518641e89ea83f10372fba19
Autor:
María Eva Mingot-Castellano, Gloria García-Donas Gabaldon, Rosa María Campos-Álvarez, Begoña Pedrote-Amador, Josefa Luis Navarro, María Yera Cobo, Gloria Moreno Carrasco, Reyes Jimenez-Bárcenas, On Behalf of Gacc (Grupo Andaluz de Coagulopatías Congénitas)
Publikováno v:
HemaSphere, Vol 7, p e35944fd (2023)
Externí odkaz:
https://doaj.org/article/f0cf8a35565948a4b9b49e58cb0a4a73
Autor:
Obdulia García-Olmedo, Reyes Jiménez-Bárcenas, Pedro Muriel-Cueto, María J. Martínez, José M. Baena-Cañada
Publikováno v:
Nature Reviews Clinical Oncology. 7:55-58
This Case Study describes a patient with breast cancer who was treated with capecitabine and experienced a severe adverse event when treated with brivudin for a herpes infection. The authors discuss drug–drug interactions and management of the asso
Autor:
Tomás José González-López, Abelardo Bárez, María Calbacho, Mónica Martín-Salces, José Ramón González-Porras, Arancha Alonso, Cristina Pascual, Erik de Cabo, Maryam Arefi, Pilar Galan, Blanca Sanchez-Gonzalez, Reyes Jiménez-Bárcenas
Publikováno v:
Platelets. 26(1)
Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP) patients not responding to previous therapy. However, when eltrombopag is discontinued, platelet counts usually return to baseline within 2 weeks. Here, we describe the clinic
Autor:
Miguel A. Sanz, Elsa López-Ansoar, Angeles Fernández-Rodríguez, Gloria Pérez-Rus, Maria Tenorio, Cecilia Heras, Rafael Feito Alonso, Armando Luaña, María Perera, Montserrat Cortés, Laura Entrena, Estefanía Bolaños, Violeta Martínez-Robles, María Paz Martínez-Badas, Fernando Fernández-Fuentes, Silvia Bernat, José Ramón González-Porras, María Teresa Álvarez-Román, Cristina Pascual, Blanca Sanchez-Gonzalez, Gerardo Hermida, Reyes Jiménez Bárcenas, Jose Angel Hernandez-Rivas, Alberto Casaus, Pável E Olivera, Marta Gómez-Nuñez, Arancha Alonso, Isabel Caparrós, Nuria Bermejo, Javier García-Frade, María Jesús Peñarrubia, José María Bastida, Inmaculada Soto, Tomás José González-López, María Calbacho, María Yera Cobo
Publikováno v:
Blood. 126:2263-2263
Background: Eltrombopag is an oral thrombopoietin receptor agonist (TPO-RA) drug approved in primary chronic ITP. Lack of clinical trials in secondary ITP avoids a clear demonstration of its potential in terms of safety and efficacy on secondary ITP.
Autor:
Marta Ruiz Mercado, Silvia Verdesoto Cozzarelli, Cristina Calderón-Cabrera, Ramiro Núñez Vázquez, Reyes Jiménez Bárcenas, Rosario Pérez Garrido, Jose Antonio Pérez-Simón, Francisco Javier Rodríguez Martorell
Publikováno v:
Blood. 122:4776-4776
Introduction Factor XIII deficiency (FXIII) is an uncommon coagulation disorder. Congenital FXIII deficiency, generally due to mutations in F13A1 gene, presents with early life- threating hemorrhages in homozygotes. Acquired deficiency, a more rare s